By Charlotte BathDecember 10, 2019 Clinical trials continue to demonstrate that combining immunotherapy with chemotherapy and other targeted therapies can improve survival for patients with triple-negative breast cancer, according to results presented at the 21st Annual Lynn Sage Breast Cancer Symposium in…
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today,…
For postmenopausal women with HR-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider …
A study by researchers at the National Cancer Institute investigating cancer incidence in the United States between 2010 and 2019 has found that breast, colorectal,…
In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated…
Today, the FDA granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults…
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median pr…
The phase III HYPO-RT-PC reported 10-year follow-up exploring shorter course radiotherapy for localized prostate cancer. The findings were presented at ESTRO 2025
Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study…
In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated…
Two experts discuss strategies and clinical considerations when treating patients with AML who are ineligible for intensive chemotherapy as well as those who are eligible…
